Unless otherwise specified the content of this web site is commentary, not investment research. If you buy the stock of any biotechnology or medical device company publicly traded on the Australian Stock Exchange or on any other Exchange, you need to do your own homework, and I mean, do your own homework. I'm not responsible if you lose money.
The stocks of biotechnology and medical device companies without revenue streams from product sales or ongoing service revenue should always be regarded as speculative in character.
Since most biotechnology and medical device companies listed on the Australian Securities Exchange fit this description, the 'term' speculative can reasonably be applied to the entire sector.
The fact that the intellectual property base of most biotechnology and medical device lies in science not generally regarded as accessible to the layman adds further to the riskiness with which the sector ought to be regarded.
Investors are advised to be cognisant of this risk before buying any of the stocks mentioned on this web site.
The stocks of biotechnology and medical device companies without revenue streams from product sales or ongoing service revenue should always be regarded as speculative in character.
Since most biotechnology and medical device companies listed on the Australian Securities Exchange fit this description, the 'term' speculative can reasonably be applied to the entire sector.
The fact that the intellectual property base of most biotechnology and medical device lies in science not generally regarded as accessible to the layman adds further to the riskiness with which the sector ought to be regarded.
Investors are advised to be cognisant of this risk before buying any of the stocks mentioned on this web site.
Copyright © 2016 NDF Research
